Close Menu

UPenn

Expanded Indications

The FDA has expanded the indications for both AstraZeneca's PARP inhibitor Lynparza and Myriad Genetics' BRACAnalysis CDx test, as GenomeWeb reports.

In Nucleic Acids Research this week: Planteome database of reference plant ontologies and other data; algorithm to find rearrangements in cancer genomes; and more.

Penn bioinformaticians are testing REALGAR, an application to simplify searches of GWAS, WGS, RNA-seq, and other test results for wet-lab researchers.

University of Pennsylvania researchers sequenced single mitochondria, which they noted could be used to track the development of mitochondrial disease.

Investigators have established hundreds of patient-derived xenografts, cell lines, and tumor samples, which appear to represent a wide range of melanoma molecular subtypes.

In the African American arm of a new GWAS, a risk variant in the SEMA3A gene was associated with both alcohol dependence disorder and major depressive disorder.

A genome-wide association study involving almost 1,600 African individuals led to diverse skin pigmentation-associated loci with varied effects on the complex trait.

A new set of papers reveals a range of gene expression influencers, identified using thousands of samples collected for the Genotype-Tissue Expression project.

Beyond BRCA

Mutations in other genes like PALB2 also confer breast cancer risk, the Philadelphia Inquirer writes.

Using data for 34 individuals, researchers tallied human DNA methylation variation across Yakut, Cambodian, Pathan, Mozabite, and Mayan populations.

Pages

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.